Klotho Neurosciences, Inc. Common Stock
Symbol: KLTO (NASDAQ)
0.86
▲ (10.53%) 0.082
Company Description:
Klotho Neurosciences Inc is in the development of essential medicines for the treatment of chronic diseases: Cancer, Cardiovascular, and Neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Company pipeline includes KLTO 101, KLTO 202, KLTO 301.
Key Stats
- Today's Open: $0.7601
- Today's High: $0.9
- Today's Low: $0.762
- Today's Volume: 2.32M
- Yesterday Close: $0.779
- Yesterday High: $0.8119
- Yesterday Low: $0.76
- Yesterday Volume: 1.07M
- Last Min Volume: 0
- Last Min High: $0.861
- Last Min Low: $0.861
- Last Min VWAP: $0
Company Profile
- Name: Klotho Neurosciences, Inc. Common Stock
- Website: https://www.klothoneuro.com
- Listed Date: 2024-06-24
- Location: NEW YORK, NY
- Market Status: Active
- CIK Number: 0001907223
- SIC Code: 2836
- SIC description: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
- Market Cap: $31.39M
- Round Lot: 100
- Outstanding Shares: 36.49M
- Asset Type: CS
RECENT FILINGS FOR KLTO
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-08-14 | NT 10-Q | View |
| 2025-08-12 | 8-K | View |
| 2025-08-08 | 4 | View |
| 2025-08-08 | 4 | View |
| 2025-08-08 | 4 | View |
| 2025-08-08 | 4 | View |
| 2025-08-08 | 4 | View |
| 2025-08-08 | 4 | View |
| 2025-07-28 | 424B5 | View |
| 2025-07-28 | 424B3 | View |
| 2025-07-28 | 424B3 | View |
| 2025-07-25 | EFFECT | View |
| 2025-07-23 | 8-K/A | View |
| 2025-07-22 | 8-K | View |
| 2025-07-18 | 8-K | View |
| 2025-07-10 | 8-K | View |
| 2025-07-07 | S-3 | View |
| 2025-07-02 | SCHEDULE 13G/A | View |
| 2025-07-02 | SCHEDULE 13G | View |
| 2025-06-30 | 8-K | View |
Latest News on KLTO